BEDFORD, Mass., Aug. 21, 2012 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced that today it hosted Senator Richard Blumenthal (D-Conn.) and Rep. Chris Murphy (D-CT 5) at the Company's women's imaging manufacturing facility in Danbury, CT. The Senator and Representative participated in a discussion with local breast cancer leaders, saw a demonstration of Hologic's newest technology, Dimensions 3D mammography (breast tomosynthesis) and toured the Company's manufacturing plant.
As a vocal proponent of breast cancer screening and annual mammography exams, Senator Blumenthal emphasized the important role Hologic plays in developing cutting-edge healthcare solutions for women and also in powering the local economy.
Connecticut has been a leader in promoting women's breast health. The state in 2009 became the first to enact a law requiring doctors to provide women with a breast density score after their mammograms. Dense breast tissue can make it more difficult to interpret a 2D mammogram, as breast cancer has the ability to hide behind the dense tissue.
Dr. Liane Philpotts, chief of Breast Imaging at the Yale University School of Medicine, was among those at Hologic's manufacturing facility in Danbury who discussed her experience with the Company's advanced Dimensions 3D breast tomosynthesis system. Smilow Cancer Hospital at Yale-New Haven was the first facility in Connecticut to offer Hologic's new screening and diagnosis tool.
"With Hologic's 3D technology, we can see the entire breast more clearly in one millimeter slices," said Dr. Philpotts. "This allows us to find additional cancers earlier and also dismiss ambiguous spots that are actually normal breast tissue."
Dr. Philpotts led a Yale-New Haven Hospital study that showed adding 3D to a screening mammography exam reduced recall rates by 40 percent. With conventional 2D mammography systems, overlapping breast tissue can hide small cancers or alternately can cause normal areas to look suspicious. Hologic's Dimensions 3D mammography allows radiologists to identify and characterize individual breast structures without the confusion of overlapping tissue and gives the doctors the increased ability to detect cancer and rule out non-cancerous tissue without additional imaging.
"We are honored to host Senator Blumenthal at Hologic and to show him the cutting-edge advancements we are developing to help women live longer, stronger, healthier lives," said Rob Cascella, President and Chief Executive Officer of Hologic. "We believe 3D mammography is the most important advancement for mammography to date for the early detection of breast cancer and we look forward to ensuring women across the state and the world have access to our groundbreaking technology."
Hologic's Dimensions 3D system was approved by the U.S. Food and Drug Administration in February 2011 and is available to millions of women throughout the United States. In addition to the more than 300 sites that have a 3D system in the U.S., the technology is installed in hospitals and imaging centers in 26 countries on six continents. The product was approved for sale in Europe and other countries recognizing the CE mark in 2009.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic and Dimensions and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Dimensions system. There can be no assurance the tests or systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner as the actual effect of the use of the tests and systems can only be determined on a case-by-case basis depending on the particular circumstances and installation in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
 Philpotts, L.; Raghu, M.; Durand, M.; Hooley, R.; Vashi, R.; Horvath, L.; Geisel, J.; Butler, R. Yale University School of Medicine. Initial Experience With Digital Breast Tomosynthesis in Screening Mammography. Presented May 3, 2012 at American Roentgen Ray Society Annual Meeting.
Hologic Media Contacts:
SOURCE Hologic, Inc.